Categories: Pharma & Healthcare
Format :
Immuno Oncology Assays Market Snapshot
“The Immuno Oncology Assays Market is estimated to increase at a CAGR of 11.14% from $ 6.74 billion in 2023 to $ 11.67 billion by 2030.”
Next-generation sequencing applications include immuno oncology tests, which maintain cell morphology and health for real-time measurements or continuous analysis. Examples include tumor killing assays, T cell assays, tumour cell assays, natural killer cell assays, macrophage assays, and dendritic cell assays.
High-throughput platform research aids oncology and immunotherapy research by studying immune cell regulation, including cell activation, proliferation, fatigue, chemotaxis, and cytokine response. Assays offer methods for studying immune cell population changes and can be expanded for in vivo studies with CAR-T, immune-checkpoint inhibitors, and other immune-modulators.
Axion's live-cell analysis tools can streamline immuno-oncology research by assessing potential candidates quickly and effectively. These tools can help speed up the development of life-saving medicines targeting and destroying tumours using the body's immune system. They can also help in exploring immunomodulators and measuring CAR cell death in solid and liquid tumors.
The global immuno-oncology tests market is expanding rapidly due to rising cancer burdens and a focus on innovative treatments. However, challenges like a shortage of qualified specialists and an unfriendly regulatory environment are expected to hinder the market's growth, hindering its growth.
>>>Download Sample Report Now: https://marketreportservice.com/request-sample/immuno-oncology-assays-market-54645
Market Dynamics
Growth Drivers
The global immuno-oncology tests market is expanding rapidly due to rising cancer burdens and a focus on innovative treatments. However, challenges like a shortage of qualified specialists and an unfriendly regulatory environment are expected to hinder the market's growth, hindering its growth.
The global immuno-oncology tests market is expected to grow due to the growing focus on discovering innovative cancer treatments. Immuno-oncology involves using the body's immune system to target and destroy cancer cells, aiming for precision cancer treatment. Researchers are exploring novel cancer-fighting strategies in this field.
Restraints
Opportunities
The global immuno-oncology assays market is expected to see growth opportunities due to increased R&D activities. Singapore's first integrated translational R&D hub, established in 2019, uses biochemical innovation and research data analytics to develop new diagnostic methods.
Agilent Technologies received approval from the South Korea Ministry of Food and Drug Safety in June 2022 for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic for identifying patients with NSCLC, suitable for first-line monotherapy with KEYTRUDA.
Immuno Oncology Assays Market Segment Analysis
The immunoassay segment is predicted to dominate the market due to its ability to measure the presence and concentration of large proteins and antibodies produced by cancer patients. The segment's growth is driven by the increased cancer burden, new product approvals, and launches by leading players, contributing to its significant market share.
The immuno-oncology tests market, categorized into immunoassay, PCR, NGS, Flow Cytometry, and others, is expected to dominate due to rising cancer incidence globally, primarily used in pharmaceutical, drug research, and disease diagnosis sectors.
The Lung Cancer Research Foundation predicts that by 2022, 236,740 US individuals will be diagnosed with lung cancer, with 1 in every 16 diagnosed throughout their lifetime. The research suggests that immunoassays will be crucial for accurately identifying cancer, enhancing care and reducing the burden of cancer patients.
New product approvals and launches, such as Nonagen Bioscience's Oncuria immunoassay for bladder cancer, contribute to market growth. The multiplex urine test detects 10 biomarkers linked to bladder cancer, indicating significant growth in the segment over the forecast period.
Immuno-oncology, the study and development of cancer treatments using the body's immune system, is expanding due to the rise in cancer incidence. The European cancer burden is expected to reach 3.36 million new cases by 2040, and the increasing use of targeted therapy is driving market expansion. Assays determine therapeutic antibodies, anti-drug antibodies, and soluble protein biomarkers, the market for tests also grows.
Competitive Landscape of the Immuno Oncology Assays Market Analysis
New Developments in Immuno Oncology Assays Market
Oct. 04, 2023, QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QIAGEN announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay. Epstein-Barr virus (EBV), or human herpes virus 4, is estimated in various epidemiological studies to be positive in more than 90% of the world’s population and is a significant pathogen in organ transplant recipients.
March 15, 2022, Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
Illumina, Inc. announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients across the continent.
24-Jan-2023 Charles River Laboratories, Inc - Make or Break: Immuno-Oncology Therapeutic Strategies to Overcome T Cell Exhaustion
Our recent virtual immuno-oncology symposium featured a panel of experts highlighting developments in immuno-oncology with a focus on T cell exhaustion in response and resistance to treatment. Several topics were covered providing a comprehensive overview of the emerging trends to improve the efficacy and duration of response to immuno-oncology therapies. In case you missed the presentations they are now available on-demand below.
Regional Outlook
North America is expected to experience strong growth due to the presence of prominent companies, high cancer frequency in the region, and developed healthcare infrastructure. Government initiatives and research alliances are expected to support market expansion. The National Institutes of Health predicts 1,918,030 new cancer cases by the end of 2022, while Health Canada predicts 233,900 Canadians will be diagnosed with cancer in June 2022, with 85,100 dying.
Agilent Technologies Inc.'s Ki-67 IHC MIB-1 pharmDx, approved by the FDA in October 2021, aids in identifying patients with early breast cancer at high risk of recurrence. This tool is ideal for patients considering adjuvant treatment with Verzenio in combination with endocrine therapy. New immune-oncology assay methodologies broaden usage, driving market expansion in North America during the forecast period.
Asia Pacific is expected to remain the fastest-growing market for immuno-oncology assay launches due to increased acceptance of targeted therapy, rising cancer incidence, and population growth. The World Health Organisation reports that developing countries have two to three times more ICU-acquired infections than developed ones.
Segments Covered in the Immuno Oncology Assays Market Report
By Product
By Technology
By Indication
By Application
The above information has been provided for the following regions and countries:
North America
Europe
Asia Pacific
Latin America
MEA
Frequently Asked Questions
What is the expected growth rate of the Immuno Oncology Assays market over the next 7 years?
The Immuno Oncology Assays Market is estimated to increase at a CAGR of 11.14% from $ 6.74 billion in 2023 to $ 11.67 billion by 2030.
Who are the major players in the Immuno Oncology Assays market and what is their market share?
Illumina, Inc.,Qiagen Nv.,Charles River Laboratories, Inc.,F. Hoffmann-La Roche Ltd.,Agilent Technologies, Inc.,Nanostring Technologies, Inc.,Perkinelmer, Inc.,Bio-Rad Laboratories, Inc.,Thermo Fisher Scientific, Inc.,Sartorius Ag, are prominent players operating and dominating in the market.
What is the demand projection for Immuno Oncology Assays by 2030?
Demand for Immuno Oncology Assays is projected to reach a market value of US$ 11.67 billion by 2030-end.
What is the sales growth projection for Immuno Oncology Assays?
Revenue from sales of Immuno Oncology Assays is projected to increase at a CAGR of 11.14% through 2030.
1.SUMMARY
1.1. Immuno Oncology Assays Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
3.1. Overview of Immuno Oncology Assays
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Immuno Oncology Assays
3.7 Challenges associated with Immuno Oncology Assays
3.8. Future Perspectives.
4.1. Methodology
4.2 Immuno Oncology Assays: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
6.1. Partnership Models
6.2. Immuno Oncology Assays: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
7.1. Methodology and Key Parameters
7.2. Immuno Oncology Assays: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
8.1. Analysis Methodology and Key Parameters
8.2. Immuno Oncology Assays: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Immuno Oncology Assays
Segments Covered in the Immuno Oncology Assays Market Report
By Product
By Technology
By Indication
By Application
The above information has been provided for the following regions and countries:
North America
Europe
Asia Pacific
Latin America
MEA
Research Methodology
Base Year:2022
Historical Data:2018-2022
No of Pages:123
Single User
Multi User
Corporate User
Only one user can access the report. It cannot be printed or shared. Delivery in online PDF.
US $ 2499
Multiple users can access the report. It cannot be printed or shared. Delivery in online PDF.
US $ 3499
The entire organization can use the report. It can be printed and shared. Delivery in PDF and Excel. Free update of the report after 1 year.
US $ 4499
Email: [email protected]
We are headquartered in the United States and have a strong workforce in India. We also have business development and customer retention offices in the US, Germany, the UK, and other countries.
As an independent brand, Market Report Service Research has been serving the needs of businesses around the world since 2021. MRS parent organization has a 10+ year history. To date, MRS has sold market research reports to over 3000 clients and 67% of the Fortune 500 have purchased the report at least once.
MRS is the leading publisher of market research reports. We have a strong team of around 500 market research consultants who use in-house research methods combined with primary and secondary research to produce credible market research reports. MRS reports are actually hosted by leading research report aggregators.
To help our clients find the most relevant market research reports, the MRS website marketreportservice.com has a very intuitive search function. Type in the name of the report you're looking for and some suggestions will automatically appear. You can select from the suggestions or press Enter to see a detailed list.
Search is the first step in finding the right report, but the agent is live chat and he is available 24/7 to help you with any questions you may have. In addition to real-time chat, 24/7 contact is also available. You can also email your research requirements to [email protected] contact-us. We will get back to you shortly.
MRS respects your decision to conduct due diligence before ordering a report. Therefore, we provide a sample problem report for your review and evaluation.
In addition, to report templates, our in-house market research reporting team is available for pre-sales calls. We provide our customers with transparent information to help them choose the best option for their organization.
In addition to emailing sample reports, we will make demos of past issues available if needed. Given the confidential and intangible nature of the reports, demonstrations of these reports are provided only in a secure environment through our online meeting platform.
Unless otherwise stated, the prices posted on our website are used for global market analysis. MRS strives to provide market research at affordable prices. Our reports are priced to reflect this commitment.
The fee structure for the report is based on the complexity of the task, the number of consultants involved/who will be involved in writing the report, the cost of the primary interview and survey, and the cost of the secondary survey.
Custom projects have different prices and we discuss these costs confidentially with you.
MRS recommends a global report due to market interconnectedness and relative impact but understands that clients may have different or limited requirements.
MRS, having determined that the accuracy of the report is not compromised, provides the client with the ability to extrapolate certain sections of the report. You can discuss your unique requirements with our business development personnel and research specialists who will suggest the best options for you, both in terms of scope and price.
Sign up today for tips and latest news
and exclusive special offers.